Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care

• by Yanfeng Song, Xiaofei Zhou, Lina Wang

• June 9, 2026

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

• by Alessandro Criscimanna, Jacques-Emanuel Galimard, Isabel Sánchez-Ortega, Patrick J. Hayden, Laurent Garderet, Anna Sureda, Fabio Ciceri, Donal P. McLornan, Krzysztof Kałwak, Antonio M. Risitano, Francesco Onida, Ibrahim Yakoub-Agha, Ali Bazarbachi, Annalisa Ruggeri

• June 3, 2026

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

• by Mark Davis

• May 6, 2026

• 18 min

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

• by Nico Gagelmann, Maximilian Merz, Laurien G. A. Baaij, Linda Koster, Jorinde D. Hoogenboom, Joanna Drozd-Sokolowska, Kavita Raj, Jürgen Kuball, Patrick J. Hayden, Florent Malard, Laurent Garderet, Annalisa Ruggeri, Donal McLornan

• March 31, 2026